- Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Takeda’s Takhzyro lowers attack rates in hereditary angioedema trial

Non-rollover patients received a 300mg dose every two weeks. Credit: ahmetturanince.